



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

## BIB DATA SHEET

CONFIRMATION NO. 8871

SERIAL NUMBER	FILING or 371(c) DATE	CLASS	GROUP ART UNIT	ATTORNEY DOCKET NO.
10/510,531	03/30/2005 RULE	514	1628	ON/4-32419A
<b>APPLICANTS</b> Paul Dent, GlenAllen, VA; Steven Grant, Richmond, VA; Geoffrey Krystal, Richmond, VA; Chunrong Yu, Richmond, VA;				
<b>** CONTINUING DATA *****</b> This application is a 371 of PCT/IB03/01418 04/04/2003 which claims benefit of 60/371,330 04/10/2002				
<b>** FOREIGN APPLICATIONS *****</b>				
<b>** IF REQUIRED, FOREIGN FILING LICENSE GRANTED **</b>				
Foreign Priority claimed	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	<input type="checkbox"/> Met after Allowance	STATE OR COUNTRY	SHEETS DRAWINGS
35 USC 119(a-d) conditions met	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		VA	0
Verified and	/MARCOS L SZNAIDMAN/			TOTAL CLAIMS
Acknowledged	Examiner's signature	Initials		2
<b>INDEPENDENT CLAIMS</b>				
<b>ADDRESS</b> NOVARTIS CORPORATE INTELLECTUAL PROPERTY ONE HEALTH PLAZA 101/2 EAST HANOVER, NJ 07936-1080 UNITED STATES				
<b>TITLE</b> Combination of glivec (sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol, in the treatment of cancer				
<b>FILING FEE RECEIVED</b> 1080	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:		<input type="checkbox"/> All Fees	
			<input type="checkbox"/> 1.16 Fees (Filing)	
			<input type="checkbox"/> 1.17 Fees (Processing Ext. of time)	
			<input type="checkbox"/> 1.18 Fees (Issue)	
			<input type="checkbox"/> Other _____	
		<input type="checkbox"/> Credit		